Coronavirus Pandemic: The Vaccine As Exit Strategy – A Global Hurdle Race Against Time with a Split Jury

[Francisco Colman Sercovich] ...The markets of the poorest countries, those most affected by prior pandemics thus far, are not profitable enough for wealthy countries-based multinationals to justify engaging in vaccine R&D. Beyond health-related imperatives, the large subsidies being swiftly granted by wealthy countries now in order to not just shorten schedules but also, perhaps for the most part, to ensure domestic production capacity and control of intellectual property rights, are a glaring recognition of the market failures involved and the ensuing need for public intervention -- albeit often tinted by a narrow-minded nationalism.